Diabetes Market Research Reports & Industry Analysis
Glucose monitors have a major consumer-marketing component. While physicians may prescribe a monitor, the patient ultimately has the choice of which monitor s/he uses. Insulin provides very little consumer choice. The treatment regimen prescribed by the physician must be followed and there are very few market options. With Eli Lilly and Novo Nordisk being the two largest producers of insulin, it is highly likely that an insulin user will wind up using one of their products. As time goes by, the options of oral insulin and more intranasal insulin products may offer insulin dependent diabetics more variety in terms of products and delivery methods.
Hypoglycemic agents abound and vary in their composition and mode of action. For the most part, advanced cases of Type 2 diabetes require more than one of these drugs in order for the patient to maintain glycemic control. Because of the wide variety of these products, there is some room for pharmaceutical companies to influence diabetics toward using their products. In the end, the physician may have the last word, but that does not mean that the patient will stay with a physician who does not acquiesce to his/her wishes.
Diabetes Industry Research & Market Reports
-
Blood Ketone Meter Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
... once primarily used in clinical settings, are now becoming essential tools for a broader consumer base that includes fitness enthusiasts, ketogenic diet followers, and those managing chronic health conditions. Their role in real-time ketone tracking ... Read More
-
Insulin Pens, Syringes, Pumps And Injectors Global Market Report 2025
... insulin pens, syringes, pumps and injectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to ... Read More
-
Insulin Pumps
... CAGR of 7.0% over the analysis period 2024-2030. Tethered Pumps, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$15.0 Billion by the end of the analysis ... Read More
-
Digital Diabetes Management
... at a CAGR of 18.6% over the analysis period 2024-2030. Devices, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$46.7 Billion by the end of the ... Read More
-
Insulin Storage Devices
... at a CAGR of 7.5% over the analysis period 2024-2030. Battery Operated Devices, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$996.0 Million by the end ... Read More
-
Metabolic Health
... cutting-edge products designed to optimize energy levels and support a healthier lifestyle. It will include expert insights on how diet, exercise, and sleep impact metabolic health to the newest research on food supplements and interventions. Read More
-
Diabetic Shoes
... CAGR of 8.1% over the analysis period 2024-2030. Online, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$10.6 Billion by the end of the analysis period. ... Read More
-
Diabetes Injection Pens
... at a CAGR of 5.7% over the analysis period 2024-2030. Insulin Pens, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$8.2 Billion by the end of ... Read More
-
Artificial Pancreas Device Systems
... 2030, growing at a CAGR of 18.8% over the analysis period 2024-2030. Threshold Suspended Device Systems, one of the segments analyzed in the report, is expected to record a 18.8% CAGR and reach US$1.2 Billion ... Read More
-
In-vivo CRO Market Report by Type (Rodent, Non-Rodent), GLP Type (Non-GLP, GLP Toxicology), Indication (Autoimmune/Inflammation Conditions, Pain Management, Oncology, CNS Conditions, Diabetes, Obesity, and Others), and Region 2025-2033
... The growing prevalence of chronic diseases worldwide and the increasing R&D expenditure by pharmaceutical companies are propelling the market growth. In-vivo contract research organizations (CROs) are institutions that conduct extensive biopharmaceutical research on a contractual ... Read More
-
Injection Pens
... CAGR of 5.9% over the analysis period 2024-2030. Disposable Injection Pens, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$50.0 Billion by the end of the ... Read More
-
Diabetes Drugs
... CAGR of 9.3% over the analysis period 2024-2030. Oral Drugs, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$163.4 Billion by the end of the analysis ... Read More
-
Continuous Glucose Monitoring Systems
... 2030, growing at a CAGR of 15.9% over the analysis period 2024-2030. Sensors, one of the segments analyzed in the report, is expected to record a 14.6% CAGR and reach US$5.4 Billion by the end ... Read More
-
Rare Endocrine Disease Treatment
... 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Acromegaly, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$5.7 Billion by the end ... Read More
-
Diabetes Diagnostics
... CAGR of 8.5% over the analysis period 2024-2030. Test Strips, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$14.7 Billion by the end of the analysis ... Read More
-
Blood Glucose Monitoring Systems
... 2030, growing at a CAGR of 10.0% over the analysis period 2024-2030. Self-Monitoring, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$21.4 Billion by the end ... Read More
-
Glucose Monitoring Devices
... at a CAGR of 4.6% over the analysis period 2024-2030. Self-Monitoring Devices, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$11.3 Billion by the end of ... Read More
-
Human Insulin
... CAGR of 6.8% over the analysis period 2024-2030. HI Drugs, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$70.6 Billion by the end of the analysis ... Read More
-
Metabolic Disorder Therapeutics
... at a CAGR of 6.9% over the analysis period 2024-2030. Diabetes, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$91.9 Billion by the end of the ... Read More
-
Smart Insulin Pens and Pumps
... Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Pumps, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$7.9 Billion by ... Read More
-
Desmopressin
... 5.6% over the analysis period 2024-2030. Injectable Solution, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$866.1 Million by the end of the analysis period. Growth ... Read More
-
Insulin Patch Pumps
... at a CAGR of 9.8% over the analysis period 2024-2030. Basal & Bolus, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$1.4 Billion by the end ... Read More
-
Blood Glucose Meters
... at a CAGR of 6.6% over the analysis period 2024-2030. Self-Monitoring, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$36.8 Billion by the end of the ... Read More
-
Insulin Pens
... CAGR of 7.2% over the analysis period 2024-2030. Disposable, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$11.6 Billion by the end of the analysis period. ... Read More
-
Diabetic Retinopathy Treatment
... at a CAGR of 5.0% over the analysis period 2024-2030. Non-Proliferative Diabetic Retinopathy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.5 Billion by the end ... Read More
Research Assistance
